| ID Source | ID |
|---|---|
| PubMed CID | 1008368 |
| CHEMBL ID | 1588059 |
| CHEBI ID | 149832 |
| Synonym |
|---|
| MLS000544331 , |
| smr000160480 |
| OPREA1_153607 |
| AN-153/12400002 |
| methyl 4-{[2-(methylsulfanyl)-6,7-dihydro-1h-[1,4]dioxino[2,3-f]benzimidazol-1-yl]carbonyl}phenyl ether |
| (4-methoxyphenyl)-(2-methylsulfanyl-6,7-dihydro-[1,4]dioxino[2,3-f]benzimidazol-3-yl)methanone |
| CHEBI:149832 |
| HMS2429D16 |
| sr-01000692665 |
| SR-01000692665-2 |
| CHEMBL1588059 |
| AKOS024367415 |
| cid_1008368 |
| (4-methoxyphenyl)-[2-(methylthio)-6,7-dihydro-[1,4]dioxino[2,3-f]benzimidazol-3-yl]methanone |
| bdbm32834 |
| (4-methoxyphenyl)[2-(methylsulfanyl)-6,7-dihydro-1h-[1,4]dioxino[2,3-f]benzimidazol-1-yl]methanone |
| Role | Description |
|---|---|
| anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| benzodioxine | Any organic heterobicyclic compound containing ortho-fused benzene and dioxine rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 26.6514 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.0115 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 19.7347 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 26.6195 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.1189 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| PINK1 | Homo sapiens (human) | Potency | 5.6234 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.5481 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| Parkin | Homo sapiens (human) | Potency | 5.6234 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| P53 | Homo sapiens (human) | Potency | 19.9526 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 14.1254 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| coagulation factor XI | Homo sapiens (human) | IC50 (µMol) | 3.5062 | 0.0497 | 1.4500 | 3.5062 | AID846 |
| prothrombin | Homo sapiens (human) | IC50 (µMol) | 0.9553 | 0.0010 | 3.3170 | 14.6895 | AID1215 |
| 3C-like protease, partial | Infectious bronchitis virus | IC50 (µMol) | 1.0850 | 1.0850 | 5.6067 | 9.8110 | AID1890 |
| kallikrein-5 preproprotein | Homo sapiens (human) | IC50 (µMol) | 1.3592 | 1.3592 | 11.3060 | 50.0000 | AID1431 |
| Neutrophil elastase | Homo sapiens (human) | IC50 (µMol) | 3.5062 | 0.0063 | 2.0734 | 22.3780 | AID846 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protease binding | Neutrophil elastase | Homo sapiens (human) |
| transcription corepressor activity | Neutrophil elastase | Homo sapiens (human) |
| endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| serine-type endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| protein binding | Neutrophil elastase | Homo sapiens (human) |
| heparin binding | Neutrophil elastase | Homo sapiens (human) |
| peptidase activity | Neutrophil elastase | Homo sapiens (human) |
| cytokine binding | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| cytoplasm | Neutrophil elastase | Homo sapiens (human) |
| cytosol | Neutrophil elastase | Homo sapiens (human) |
| cell surface | Neutrophil elastase | Homo sapiens (human) |
| secretory granule | Neutrophil elastase | Homo sapiens (human) |
| azurophil granule lumen | Neutrophil elastase | Homo sapiens (human) |
| specific granule lumen | Neutrophil elastase | Homo sapiens (human) |
| phagocytic vesicle | Neutrophil elastase | Homo sapiens (human) |
| collagen-containing extracellular matrix | Neutrophil elastase | Homo sapiens (human) |
| extracellular exosome | Neutrophil elastase | Homo sapiens (human) |
| transcription repressor complex | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||